

CROHN'S & ULCERATIVE COLITIS REFERRAL FORM
Adult Non-Infusion Drugs

Prescriber, please sign and fax completed form to 713.704.3841
For questions, please call 281.698.6100

SHIP TO: Patient
 Office (1st dose)
 Office (All doses)

Patient Information

****Please include copy of prescription and medical insurance card, front and back****

Patient Name: _____ Date of Birth: _____
Street Address: _____ Phone: _____
City, State, Zip: _____ Allergies: _____

Prescriber Information

Prescriber Name: _____ NPI: _____
Specialty: _____ Phone: _____
Office Street Address: _____ Fax: _____
City, State, Zip: _____ Office Contact: _____

Patient Medical Information

****Please include copies of any pertinent clinical notes and lab work****

Diagnosis (ICD-10): K50.0 (Crohn's Disease of the Small Intestine) K51.0 (Ulcerative Pancolitis) K51.8 (Other Ulcerative Colitis)
 K50.1 (Crohn's Disease of the Large Intestine) K51.2 (Ulcerative Procolitis) K51.9 (Ulcerative Colitis, unspecified)
 K50.8 (Crohn's Disease of Both Intestines) K51.3 (Ulcerative Rectosigmoiditis) Other _____
 K50.9 (Crohn's Disease, unspecified) K51.5 (Left Sided Colitis) _____

Diagnosis Date: _____ Date of negative TB Test: _____ Date of negative chest X-ray (if TB positive): _____

Previous and/or Current Medications Used to Treat this Diagnosis:

Medication Name(s)	Current Use	Start Date	End Date	Discontinue Reason (if stopped)
	<input type="checkbox"/>			<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
	<input type="checkbox"/>			<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
	<input type="checkbox"/>			<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____

Prescription Information

		Quantity	Form	Refills
<input type="checkbox"/> Cimzia (certolizumab)	Initial (if applicable) <input type="checkbox"/> Inject 400 mg subcutaneously at weeks 0, 2, and 4	<input type="checkbox"/> #6 (200 mg / 1 mL)	<input type="checkbox"/> PFS <input type="checkbox"/> Vial	No Refills
	Maintenance <input type="checkbox"/> Inject 400 mg subcutaneously every 4 weeks	<input type="checkbox"/> #2 (200 mg / 1 mL)	<input type="checkbox"/> PFS <input type="checkbox"/> Vial	Refills: _____
<input type="checkbox"/> Humira 40mg / 0.8 mL (adalimumab)	Initial (if applicable) <input type="checkbox"/> Inject 160 mg subcutaneously on day 1 and 80 mg on day 15	<input type="checkbox"/> #6 (40 mg / 0.8 mL)	<input type="checkbox"/> Pen Starter Kit <input type="checkbox"/> PFS	No Refills
	Maintenance <input type="checkbox"/> Inject 40 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 40 mg subcutaneously weekly	<input type="checkbox"/> #2 (40 mg / 0.8 mL) <input type="checkbox"/> #4 (40 mg / 0.8 mL)	<input type="checkbox"/> Pen <input type="checkbox"/> PFS	Refills: _____
<input type="checkbox"/> Humira Citrate Free 40mg / 0.4 mL (adalimumab)	Initial (if applicable) <input type="checkbox"/> Inject 160 mg subcutaneously on day 1 and 80 mg on day 15	<input type="checkbox"/> #3 (80 mg / 0.8 mL) <input type="checkbox"/> #6 (40 mg / 0.4 mL)	<input type="checkbox"/> Pen Starter Kit <input type="checkbox"/> PFS	No Refills
	Maintenance <input type="checkbox"/> Inject 40 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 40 mg subcutaneously weekly	<input type="checkbox"/> #2 (40 mg / 0.4 mL) <input type="checkbox"/> #4 (40 mg / 0.4 mL)	<input type="checkbox"/> Pen <input type="checkbox"/> PFS	Refills: _____
<input type="checkbox"/> Simponi (golimumab)	Initial (if applicable) <input type="checkbox"/> Inject 200 mg subcutaneously at week 0 and 100mg at week 2	<input type="checkbox"/> #3 (100 mg / 1 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	No Refills
	Maintenance <input type="checkbox"/> Inject 100 mg subcutaneously weekly	<input type="checkbox"/> #4 (100 mg / 1 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: _____
<input type="checkbox"/> Stelara (ustekinumab)	Initial (if applicable) <input type="checkbox"/> Infuse 260 mg intravenously over no less than one hour (≤55kg) <input type="checkbox"/> Infuse 390 mg intravenously over no less than one hour (55-85kg) <input type="checkbox"/> Infuse 520 mg intravenously over no less than one hour (≥85kg)	<input type="checkbox"/> #2 (130 mg / 26 mL) <input type="checkbox"/> #3 (130 mg / 26 mL) <input type="checkbox"/> #4 (130 mg / 26 mL)	Vials	No Refills
	Maintenance (Starting 8 weeks after initial infusion, if applicable) <input type="checkbox"/> Inject 90 mg subcutaneously every 8 weeks	<input type="checkbox"/> #1 (90 mg / 1 mL)	PFS	Refills: _____
<input type="checkbox"/> Xeljanz (tofacitinib)	Initial (if applicable) <input type="checkbox"/> Take 10 mg by mouth twice daily for 8 weeks	<input type="checkbox"/> #60 (10 mg tablet)	Tablet	Refills: _____
	Maintenance <input type="checkbox"/> Take 5 mg by mouth twice daily <input type="checkbox"/> Take 10 mg by mouth twice daily	<input type="checkbox"/> #60 (5 mg tablet) <input type="checkbox"/> #60 (10 mg tablet)	Tablet	Refills: _____
<input type="checkbox"/> Other: _____	<input type="checkbox"/> _____	<input type="checkbox"/> _____	<input type="checkbox"/> _____	Refills: _____

Prescriber Signature (No Stamps Permitted)

By signing below, I authorize Memorial Hermann Specialty Pharmacy to serve as my designated agent, if needed, to initiate and execute any applicable authorization processes with medical and prescription insurance companies. To prohibit generic substitution write "brand necessary" or "brand medically necessary" on the face of the prescription in your own handwriting.

Prescriber's Signature : _____ Date: _____

Confidentiality Notice – Warning: Unauthorized interception of this fax communication could be a violation of federal and state law. The documents accompanying this fax transmission may contain information that is legally privileged. The information is intended only for use by the recipient. You are hereby notified that any disclosure, copying, distribution, or taking of any action on the contents of this faxed information is strictly prohibited. If you have received this information in error, please immediately notify sender by telephone to arrange for the return of the original documents.